FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1711243923> ?p ?o ?g. }

• W1711243923 abstract "The 7th report of the Joint National Committee (JNC 7) on the detection, prevention, and treatment of hypertension (HTN) recommends a thiazide diuretic, used singly or in combination with other antihypertensive medications, as initial therapy for patients with HTN.1 Although physicians tend to view the thiazides as a homogenous class of diuretics, significant differences exist among these drugs, especially with respect to their efficacy of blood pressure lowering and, more important, the outcomes data supporting their ability to improve the long-term prognosis for HTN. Although hydrochlorothiazide continues to be US physicians' overwhelmingly favored thiazide for treating HTN, a closer look at the data suggests that its preferred status is not warranted.A recent meta-analysis adds fuel to the fire of this debate.2 The authors show that hydrochlorothiazide, at doses of 12.5 to 25 mg daily, is inferior to other classes of antihypertensive medications, and they conclude that it should not be the thiazide diuretic of first choice for treatment of HTN. How do these new data fit with what we already know and what inferences can be made from the totality of the available evidence?Our group has recently published a formal review of published literature evaluating the impact of thiazide diuretics on cardiovascular (CV) prognosis in patients with HTN.3 While studies of head-to-head comparison between thiazide diuretics are lacking, we found that hydrochlorothiazide (25 mg daily) was consistently inferior to other comparators (except atenolol—another antihypertensive agent with poor outcomes data)4 in preventing CV events.5-9 Conversely, data with chlorthalidone (12.5 to 25 mg daily)10-12 and indapamide (0.625 to 2.5 mg daily)13-15 were considerably more robust and showed unequivocal reductions in adverse CV events (Figure). These findings argue against a class effect with thiazide-type diuretics and suggest instead that diuretics with better track records (such as chlorthalidone and indapamide) should be preferentially used when a thiazide is indicated. Put differently, hydrochlorothiazide should not be a first-line thiazide because it has a relatively weak antihypertensive effect and no appreciable evidence supporting its role in improving CV prognosis and outcomes of patients with HTN. Whether or not using hydrochlorothiazide at higher doses (50 mg daily) would be more beneficial is unclear because such high daily doses have been associated with higher risk of hypokalemia and sudden cardiac death.Figure.Data summary from landmark outcomes studies on the impact of thiazide diuretics (hydrochlorothiazide, chlorthalidone and indapamide) on major cardiovascular endpoints: (a) total mortality, (b) CV mortality, (c) CVA.The reasons for this obvious disconnect between the poor performance of hydrochlorothiazide in improving the long-term outcomes of patients with HTN and its highly favored status among physicians are not entirely clear. Hydrochlorothiazide is mostly used out of habit and/or the ease of its widely recognized abbreviations (HCT or HCTZ).16,17 Moreover, hydrochlorothiazide is available in a host of fixed-dose combinations with a variety of other blood-pressure lowering medications, likely another key reason for its widespread use. Using indapamide or chlorthalidone combined with other antihypertensive agents with more compelling outcomes data (such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) will not only improve blood pressure (BP) control, but is also likely to impact CV prognosis favorably. Moreover, this combination is likely to mitigate the risk of hypokalemia, a potential complication typically seen at higher doses of more potent thiazides. The use of antihypertensive combinations becomes particularly important when we realize that two-thirds of patients with HTN require at least 2 medications to achieve BP targets.18As a final practical matter, all of these thiazide diuretics are available for $4 per month; therefore, cost should not be a significant barrier to using either chlorthalidone or indapamide instead of hydrochlorothiazide, even for those without insurance coverage for prescription medications.With scientific evidence consistently indicating that hydrochlorothiazide is suboptimal for reducing the risk of adverse CV events and optimizing BP control, its use as the thiazide of choice for patients with HTN becomes exceedingly hard to justify. On the other hand, the available evidence strongly supports the use of chlorthalidone19 or indapamide when a thiazide diuretic is indicated for HTN." @default.
• W1711243923 created "2016-06-24" @default.
• W1711243923 creator A5024111381 @default.
• W1711243923 creator A5059582018 @default.
• W1711243923 creator A5088837170 @default.
• W1711243923 date "2012-01-01" @default.
• W1711243923 modified "2023-09-24" @default.
• W1711243923 title "The Last Nail in Hydrochlorothiazide's Coffin?" @default.
• W1711243923 cites W1592471891 @default.
• W1711243923 cites W1976784984 @default.
• W1711243923 cites W2026646790 @default.
• W1711243923 cites W2046268717 @default.
• W1711243923 cites W2069268487 @default.
• W1711243923 cites W2081372556 @default.
• W1711243923 cites W2103881469 @default.
• W1711243923 cites W2109861453 @default.
• W1711243923 cites W2110880027 @default.
• W1711243923 cites W2117529378 @default.
• W1711243923 cites W2128086052 @default.
• W1711243923 cites W2146851676 @default.
• W1711243923 cites W2156121263 @default.
• W1711243923 cites W2157677292 @default.
• W1711243923 cites W2404212513 @default.
• W1711243923 cites W2562329777 @default.
• W1711243923 cites W3110805540 @default.
• W1711243923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3307504" @default.
• W1711243923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22438773" @default.
• W1711243923 hasPublicationYear "2012" @default.
• W1711243923 type Work @default.
• W1711243923 sameAs 1711243923 @default.
• W1711243923 citedByCount "1" @default.
• W1711243923 countsByYear W17112439232013 @default.
• W1711243923 crossrefType "journal-article" @default.
• W1711243923 hasAuthorship W1711243923A5024111381 @default.
• W1711243923 hasAuthorship W1711243923A5059582018 @default.
• W1711243923 hasAuthorship W1711243923A5088837170 @default.
• W1711243923 hasConcept C126322002 @default.
• W1711243923 hasConcept C177713679 @default.
• W1711243923 hasConcept C2776525901 @default.
• W1711243923 hasConcept C2779918671 @default.
• W1711243923 hasConcept C2780361556 @default.
• W1711243923 hasConcept C2780437262 @default.
• W1711243923 hasConcept C71924100 @default.
• W1711243923 hasConcept C84393581 @default.
• W1711243923 hasConceptScore W1711243923C126322002 @default.
• W1711243923 hasConceptScore W1711243923C177713679 @default.
• W1711243923 hasConceptScore W1711243923C2776525901 @default.
• W1711243923 hasConceptScore W1711243923C2779918671 @default.
• W1711243923 hasConceptScore W1711243923C2780361556 @default.
• W1711243923 hasConceptScore W1711243923C2780437262 @default.
• W1711243923 hasConceptScore W1711243923C71924100 @default.
• W1711243923 hasConceptScore W1711243923C84393581 @default.
• W1711243923 hasLocation W17112439231 @default.
• W1711243923 hasOpenAccess W1711243923 @default.
• W1711243923 hasPrimaryLocation W17112439231 @default.
• W1711243923 hasRelatedWork W1813562549 @default.
• W1711243923 hasRelatedWork W1992576840 @default.
• W1711243923 hasRelatedWork W1997738446 @default.
• W1711243923 hasRelatedWork W2008671967 @default.
• W1711243923 hasRelatedWork W2009673463 @default.
• W1711243923 hasRelatedWork W2011855996 @default.
• W1711243923 hasRelatedWork W2021943556 @default.
• W1711243923 hasRelatedWork W2023682986 @default.
• W1711243923 hasRelatedWork W2064971119 @default.
• W1711243923 hasRelatedWork W2068742406 @default.
• W1711243923 hasRelatedWork W2072201193 @default.
• W1711243923 hasRelatedWork W2080818886 @default.
• W1711243923 hasRelatedWork W2085921098 @default.
• W1711243923 hasRelatedWork W2087521520 @default.
• W1711243923 hasRelatedWork W2094906554 @default.
• W1711243923 hasRelatedWork W2124057605 @default.
• W1711243923 hasRelatedWork W2997280054 @default.
• W1711243923 hasRelatedWork W56335222 @default.
• W1711243923 hasRelatedWork W83150772 @default.
• W1711243923 hasRelatedWork W2013478535 @default.
• W1711243923 isParatext "false" @default.
• W1711243923 isRetracted "false" @default.
• W1711243923 magId "1711243923" @default.
• W1711243923 workType "article" @default.